LB Pharmaceuticals Inc (LBRX)

LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing treatments for neuropsychiatric disorders. Its lead product candidate, LB-102, is N-methyl amisulpride, a modified version of the antipsychotic amisulpride that acts on dopamine D2 and D3 receptors and serotonin 5-HT7 receptors.

The company is studying LB-102 first in schizophrenia, with the aim of offering a once-daily oral therapy that retains the efficacy of the amisulpride class while improving how the drug crosses into the brain. It has also indicated interest in other conditions where this mechanism may be relevant, such as bipolar depression and other mood disorders.

LB Pharmaceuticals is based in New York City and completed its initial public offering on the Nasdaq in 2025.